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Serous Cystic Neoplasm: Do We Have to Wait Till It 
Causes Trouble?
Serous cystic neoplasm (SCN) of the pancreas is considered a benign tumor with almost no 
malignant potential. Most surgeons agree that asymptomatic SCN requires only regular 
observation. However, several complexities and interference with organ preservation during the 
operation, may develop when a huge symptomatic tumor is treated with surgery. So, the purpose 
of this study is to develop a potential management plan based on a literature review and by 
describing three recent cases of SCN of the pancreas. We suggest that SCNs be responded 
to with a timely and appropriate surgical intervention – before they require clinical attention.
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Introduction
  Ten to 20 percent of pancreatic cysts are neoplastic cysts, 
and malignant cystic neoplasms account for about 1% of 
malignant pancreatic tumors.1,2 Unlike mucinous cystic 
neoplasm or intraductal papillary mucinous neoplasm of 
the pancreas, pancreatic serous cystic neoplasm is 
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Fig. 1. (Case 1) A large tumor is compressing the adjacent splenic vein (arrow).
Fig. 2. (Case 2) Note dilatation of the distal pancreatic duct (A, arrow) and a huge duodenal ulcer (B, arrow).
considered a benign tumor with almost no malignant 
potential. Only expectant management with serial follow-up 
need be provided, and surgery is not recommended in the 
absence of symptoms. Since, George et al.3 reported the 
first case of serous cystadenocarcinoma in 1989, only about 
25 cases have been reported around the world.4
  With the development of better socioeconomic condi-
tions and of increasing concern for personal health, 
asymptomatic benign or borderline malignant cystic 
neoplasms of the pancreas are increasingly detected.5-7 In 
addition, experiences with pancreatectomy along with 
advances in surgical technique and perioperative mana-
gement have reduced operative mortality following pan-
createctomy to a level of general acceptance.8 Furthermore, 
minimally invasive (laparoscopic or robotic) pancreatec-
tomy is currently available and can be safely performed, 
and it would also be beneficial in terms of quality of life. 
Taking these facts into consideration, what would be an 
appropriate way of managing serous cystic tumor of the 
pancreas? In this report, we present three recent cases of 
serous cystic neoplasm of the pancreas and suggest a 
potential management plan based on a literature review.
Case Reports
  Case 1 was a female patient admitted to our hospital due 
to dyspnea and a palpable mass. An abdominal CT scan 
showed a huge pancreatic mass compressing adjacent 
vascular structures and intraabdominal organs (Fig. 1A). 
She underwent spleen-preserving subtotal distal pancreatec-
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Fig. 3. (Case 3) An articulating surgical instrument facilitates fine dissection of small tributary vessels between splenic vessels and
the distal pancreas (B).
Table 1. Patient presentations
Case Age Gender Symptom Surgery Size(cm) Pathology
1
2
3
58
75
65
F
M
F
Palpable mass Dyspnea
Abdominal pain Indigestion
Incidental finding
SPDP* with SRSA&SV‡
PPPD§
Robotic SPDP
11
 8
  3.2
SCA†
SCA with pancreatic 
 duct dilation
SCA
*SPDP=spleen preserving distal pancreatectomy; †SCA=serous cystadenoma; ‡SRSA&SV=segmental resection of splenic artery and 
vein; §PPPD=pylorus-preserving pancreatoduodenectomy
tomy with segmental resection of whole splenic vessels. 
The tumor was reported as a serous cystadenoma (Fig. 1B, 
C). In case 2, a patient had been followed up for a 
pancreatic serous cystic neoplasm over the last 5 years. At 
initial presentation, tumor size was about 4.5 cm without 
any symptoms. Recently, he developed abdominal pain, 
discomfort, and indigestion. Axial imaging found that the 
tumor had become enlarged, up to 8 cm in size, and 
caused dilation of the distal pancreatic duct (Fig. 2A). She 
underwent pancreatoduodenectomy. The tumor was abut-
ting the gastroduodenal artery and superior mesenteric 
vein, but did not invade surrounding major vascular 
structures. Pathologic examination found a huge duodenal 
ulcer and an 8 cm sized serous cystadenoma without 
definitive invasive features (Fig. 2B, C).
  In case 3, an incidental pancreatic tumor was found 
during evaluation of a woman's renal cyst (Fig. 3A). There 
were no symptoms related to the pathology of the 
pancreatic tail. After fully understanding the natural course 
of serous cystic neoplasm, she agreed to surgical extir-
pation. Robotic spleen-preserving distal pancreatectomy 
conserving both splenic vessels was performed (Fig. 3B). 
The pancreatic tumor was reported as a serous cystade-
noma (Fig. 3C). All cases are summarized in Table 1.
Discussion
  Most pancreatic serous cyst neoplasms are rare and 
asymptomatic, with a benign nature. However, the preva-
lence of cancer among serous cystic neoplasms is known 
to be about 3%.9 According to a recent literature review of 
serous cystadenocarcinoma,4 the median age of patients is 
68 years old (range, 52∼85 years), and the median tumor 
size is 10 cm (range, 2.5∼19 cm). This suggests that serous 
cystic neoplasm might eventually progress to large malig-
nant tumors in the elderly when left without appropriate 
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Fig. 4. Suggested approach to serous cystic tumor of the pancreas. MIS: minimally invasive surgery, *MIS may be chosen according
to the surgeon’s preference, experience, and skills. 
treatment. In addition, Tseng et al.10 observed that serous 
cystic neoplasms smaller than 4 cm at presentation grow 
slowly (only about 0.12 cm/year), whereas those larger 
than 4 cm at presentation grow much faster (1.98 cm/year). 
They also reported that larger tumors were more likely to 
develop symptoms later, suggesting that the tumor biology 
may be different according to tumor size, and that a 
pancreatic serous cystic neoplasm aggressively transforms 
as it grows. In recent clinical practice, the strategy for 
asymptomatic small serous cystic neoplasm, which used to 
be a conditional observation of a periodic axial image 
study, needs to be reevaluated. In the past, higher 
morbidity and potential mortality following pancreatectomy 
was thought to be a great obstacle in applying a surgical 
approach to asymptomatic serous cystic neoplasms. How-
ever, recent advances in surgical techniques, experiences, 
and preoperative management have reduced operative 
morbidity and mortality to generally acceptable ranges.11 In 
particular, minimally invasive (laparoscopic and robotic) 
pancreatectomy can be safely performed these days.12,13 
Long-term survival following successful pancreatectomy is 
highly expected in patients with benign and borderline 
malignant tumors. So, quality of life needs to be considered 
in choosing among surgical options.
  Cases 1 and 2 are considered as clinical outcomes of 
conditional observations of asymptomatic serous cystic 
neoplasms. The patient in case 3 was treated with func-
tion-preserving, minimally invasive pancreatectomy. Consi-
dering that the natural course of serous cystic neoplasm is 
to become large and symptomatic or to undergo malignant 
degeneration, timely surgical intervention with either 
conventional open or minimally invasive surgery is a more 
reasonable strategy for current clinical practice. We suggest 
a strategy for managing serous cystic neoplasm of the 
pancreas (Fig. 4) based on our clinical experience and a 
literature review. While tumor size matters, a surgical 
approach with minimally invasive surgery needs to be 
considered, even in cases with asymptomatic small serous 
cystic neoplasms, as they may develop, cause symptoms, 
and become malignant (Fig. 2).
  In summary, serous cystic neoplasm of the pancreas is 
rare but seems to be increasing due to easy access to 
medical care and improvements in pancreatic imaging. 
Based on a literature review and the cases presented here, 
the natural course of serous cystic neoplasm appears to be 
related to tumor size, symptoms and malignancy. Thus, we 
suggest timely and appropriate surgical intervention for 
SCNs before they require clinical attention.
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